Are Peptides Legal in the US?

"Are peptides legal?" sounds like a yes-or-no question. In the US, the real answer depends on which peptide, how it is made, who sells it and why. This guide walks through the main categories in plain English, including what changed in 2026. It is general information, not legal advice.

Key takeaways

• "Peptide" is a broad word. Legal status depends on the specific product.
• FDA-approved peptide medications, like semaglutide and tesamorelin, are legal with a prescription from a licensed pharmacy.
• Compounded peptides are legal only when a licensed pharmacy follows federal and state compounding rules. Many popular peptides do not currently qualify.
• In 2026 FDA began reviewing several popular peptides for compounding, but as of October 2026 no final rule has added them to the approved bulks list.
• "Research use only" products are not approved for people, and FDA has warned companies that market them for human use.

Four buckets of peptides

It helps to sort peptides into four groups.

Let's look at each.

FDA-approved peptide medications

These have gone through FDA review for safety, effectiveness and quality. They have official labels, called prescribing information, that list approved uses, warnings and storage rules. You can browse their status on our peptide pages.

Getting them legally means:

• A prescription from a licensed prescriber, in person or through a licensed telehealth provider
• Filling it at a state-licensed pharmacy

Doctors may sometimes prescribe approved drugs "off-label" for other uses. That is a medical decision between you and your prescriber.

Compounded peptides

Compounding is when a licensed pharmacy mixes a medication for a patient. It is legal, but federal law sets limits. A 503A pharmacy, for example, generally may compound with bulk ingredients only if they meet certain conditions, such as being part of an approved drug, having a USP monograph, or appearing on FDA's 503A bulks list. Read more in 503A vs 503B Compounding Pharmacies Explained.

FDA says compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness or quality before they are sold. FDA also warns that salt forms like semaglutide sodium or acetate are different ingredients from those in approved drugs.

What changed in 2026

This is the part with the most confusion online, so here are the facts as of October 2026.

• September 2023: FDA placed several peptides in "Category 2," meaning bulk substances that raise significant safety concerns for compounding.
• April 2026: FDA said it would remove twelve peptides from Category 2, including BPC-157, TB-500, KPV, MOTS-c, epitalon, semax, DSIP (emideltide), LL-37, GHK-Cu (injectable), dihexa, PEG-MGF and melanotan II. FDA's Category 2 page now lists these as nominations withdrawn.
• July 23-24, 2026: FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, epitalon and semax to the 503A bulks list. It voted against DSIP. FDA staff had recommended against adding all of them.
• Still to come: The committee is scheduled to review LL-37, GHK-Cu, dihexa, PEG-MGF and melanotan II before the end of February 2027.

What this means: committee votes are recommendations. FDA must still go through rulemaking, with public comment, before a substance is added to the bulks list. Legal analysts note that being removed from Category 2 does not by itself make a peptide eligible for compounding. As of October 2026, none of these peptides has been added to the list, and none is FDA-approved as a drug.

Some peptides, including GHRP-2, GHRP-6, ipamorelin and kisspeptin-10, still appeared in Category 2 on FDA's page when we checked. We cover the details in FDA Bulk Drug Substance Categories Explained. Rules may change, so check FDA's pages for updates.

"Research use only" products

Many websites sell peptides labeled "for research use only" or "not for human consumption." This label does not make them legal to use as medicine.

FDA has warned companies selling semaglutide, tirzepatide, retatrutide and other drugs this way while marketing them for people, often with dosing instructions. FDA says these products have unknown quality and may be harmful. They have no approved label, no quality checks you can trust, and no pharmacist overseeing them.

PepSteady does not link to or recommend these sellers. If you are curious about a peptide, the safe path is a conversation with a licensed prescriber. Our post Prescription Peptides vs Research Use Only Peptides goes deeper.

Sports rules are separate

Even a legal prescription can break sports rules. The 2026 WADA Prohibited List bans many peptides at all times. It names BPC-157 under non-approved substances, lists growth hormone releasing peptides and secretagogues like ipamorelin, names tesamorelin and sermorelin among GHRH analogues, and lists thymosin beta-4 and derivatives like TB-500. Tested athletes should check the current list and talk to their sport's anti-doping body. See Peptides and Athletes: What WADA Prohibits.

Questions to ask your prescriber

• Is this peptide FDA-approved, and for what use?
• If it is compounded, which pharmacy makes it, and is it licensed in my state?
• What is the legal basis for compounding this ingredient?
• Are there approved alternatives?

The bottom line

Peptides are not all legal or all illegal. FDA-approved peptide drugs are legal with a prescription from a licensed pharmacy. Compounded peptides are legal only within strict rules, and the status of popular peptides like BPC-157 is still being decided in 2026. "Research use only" products are not a legal or safe route to treatment. When in doubt, ask a licensed prescriber or pharmacist.

Sources

• FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
• FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
• FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• WADA: The Prohibited List
• DLA Piper: FDA AdComm recommends adding six peptides to bulk list (July 2026)

Frequently asked questions